Basic information on BridgeBio Pharma
Impact Score
Description BridgeBio Pharma
BridgeBio Pharma Inc. develops and commercializes therapies for genetic diseases and cancers with high unmet needs. Its focus is on advancing drug candidates from early discovery to clinical stages.BridgeBio Pharma Sustainability Performance
Climate
Society
Gender
Sustainable [100]
Almost sustainable [67-99]
Moderate [34-66]
Not sustainable [0-33]
No data
Renewable Energy
Greenhouse Gas Emissions
Supply Chain
Waste Recycling
Sustainable [100]
Almost sustainable [67-99]
Moderate [34-66]
Not sustainable [0-33]
No data
We measure the sustainability of companies based on 12 criteria.Indicators range from 0 to 100: values from 0 to 33 are shown in red (“not sustainable”), values from 34 to 66 in yellow (“moderate”), values from 67 to 99 in light green (“almost sustainable”), and a value of 100 in green (“sustainable”). Learn more about our method.
Compare BridgeBio Pharma with ...
BridgeBio Pharma
?
Impact Score
Climate
Society
Gender
Sources of sustainability performance
| Metric | Value | Unit | Year | PDF Name | PDF Page | |
|---|---|---|---|---|---|---|
CEO Pay Ratio | ||||||
| 37 | Ratio | 2025 | sec-def-14a-2025-remuneration-report.pdf | 47 | ||
| Neil Kumar, Ph.D. | 2025 | sec-def-14a-2025-remuneration-report.pdf | 27 | |||
Harassment and Discrimination at the Workplace | ||||||
| Yes | 2025 | BridgeBio_Code_Of_Conduct_October2025_NKsig-fa1560.pdf | 5 | |||
| Yes | 2025 | BridgeBio_Code_Of_Conduct_October2025_NKsig-fa1560.pdf | 13 | |||
| Yes | 2025 | BridgeBio_Code_Of_Conduct_October2025_NKsig-fa1560.pdf | 13 | |||
| Yes | 2025 | BridgeBio_Code_Of_Conduct_October2025_NKsig-fa1560.pdf | 10 | |||
Union Formation and Collective Bargaining Power | ||||||
| 0 | % | 2025 | sec-10-k-2025-annual-report.pdf | 54 | ||
Women on Board | ||||||
| 2 | people | 2025 | sec-def-14a-2025-remuneration-report.pdf | 11 | ||
| 14 | people | 2025 | sec-def-14a-2025-remuneration-report.pdf | 11 | ||
Find more sustainable companies
© 2026 money:care GmbHDisclaimerThe information provided is for informational purposes only and does not constitute an offer, recommendation, or investment advice to buy or sell financial instruments. Nor may they or any part of them be used as a basis for concluding a contract. They have been adopted in good faith from publicly accessible sources. No liability can be assumed for their accuracy. Any financial instrument referred to in this information and documents may be unsuitable for the respective investor to whom it is addressed. The recipients of such information and documents are responsible for independently evaluating and reviewing the products, assets, and financial instruments mentioned therein. Investors must make their own assessment of the suitability of the financial instruments mentioned herein based on the benefits and risks associated with the acquisition of the products, as well as on the basis of their own investment strategy and their legal, tax, and financial situation. Should readers use the content offered or follow any advice, they act on their own responsibility.The information contained in the company descriptions is generated by artificial intelligence and is for informational purposes only. While we strive for accuracy, the content may not be entirely reliable or comprehensive. We recommend cross-referencing the AI-generated content with other reliable sources to verify it and gain a more comprehensive understanding of the respective companies.Some links are affiliate links. If you click on these links and open an account, we will receive a small commission. Don't worry, you won't incur any additional costs. Thank you for your support! Reference data includes information from ESMA FIRDS that has been transformed and enriched by money:care. The use of this reference data does not constitute endorsement of or support for money:care or its products by ESMA. Fund information is based in part on publications by the respective providers and has been processed by money:care. Logos provided by Logo.dev